Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Sniff and sweat: new study tests simple ways to keep aging brains sharp

NCT ID NCT07623122

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether smell training and/or physical exercise can improve thinking, movement, and quality of life in healthy adults aged 60 and older. About 120 participants were split into four groups: usual care, smell training, exercise, or both. The goal was to understand how these activities affect the brain and body, not to treat a disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Jun 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged ≥60 years under the care of Primary Care and/or the Geriatrics Service of the Hospital Universitario de Navarra; * Normal cognitive function as determined at baseline assessment (Mini-Mental State Examination \[MMSE\] score ≥23; ≥21 for individuals without formal education); * Fluent in speaking, reading, and understanding Spanish; * Adequate olfactory function; * Adequate visual and auditory acuity to complete neuropsychological and computerized assessments; * In good general health, with no condition expected to interfere with study participation; * Willing and able to comply with study procedures and to participate for the entire study duration; * Willing to refrain from the use of scented candles, essential oils, or air fresheners during study participation. Exclusion Criteria * Refusal or inability of the participant, primary caregiver, or legal representative to provide informed consent; * Diagnosis of a neurodegenerative disease or severe dementia (Global Deterioration Scale \[GDS\] stage 6-7); * Conditions affecting the olfactory system (e.g., nasal polyps); * Life expectancy \<3 months; * History of asthma, allergies, or olfactory-triggered responses producing allergy-like symptoms (e.g., rhinorrhea, lacrimation, sneezing, or skin rash); * History of neurological disorders such as Parkinson's disease, multiple sclerosis, brain cyst, tumor, or aneurysm; * Significant medical conditions, including uncontrolled diabetes mellitus, uncontrolled hypertension, nutritional deficiencies, or thyroid disorders; * History of major psychiatric disorders such as schizophrenia, bipolar disorder, anxiety disorders, or attention-deficit/hyperactivity disorder; * History of alcohol or substance abuse or dependence within the past 2 years (DSM-IV criteria), including use of cigarettes, e-cigarettes, cigars, marijuana, or any substance that may produce odors interfering with the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive decline are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario de Navarra

    Pamplona, Navarre, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.